Developing and Evaluating a Fully Integrated Treatment Program for Comorbid Social Anxiety and Alcohol Use Disorders
CLARE|MATRIX is currently participating as the sole research site for an Investigator-initiated study, designed and led by Dr. Kate Wolitzky-Taylor of UCLA. Dr. Wolitzky-Taylor has designed a protocol aimed at evaluating the effectiveness of a fully-integrated outpatient treatment intervention for co-occurring alcohol use disorder and social anxiety disorder, as compared to the Matrix Model. CLARE|MATRIX and UCLA research staff have been working collaboratively to screen and enroll 60 participants, as well as conduct research assessments and interventions as required for the completion of the study.
CLARE|MATRIX is proud to collaborate with Dr. Wolitzky-Taylor on her quest to develop a treatment intervention that will increase the potential for more effective treatment engagement and positive treatment outcomes for individuals with comorbid alcohol use disorder and social anxiety disorder.
Partners
University of California, Los Angeles
National Institute on Alcohol Abuse and Alcoholism
Investigator
Kate Wolitzky-Taylor, PhD
Exercise in Methamphetamine Use Disorder: Dopamine Receptor Upregulation and Neural Function
CLARE|MATRIX is currently collaborating with Dr. Edythe D. London and Dr. Larissa J. Mooney to recruit participants for two intervention studies. Dr London and Dr. Mooney are seeking 166 individuals that are enrolled in inpatient programs at CLARE|MATRIX and two other treatment sites. The studies are investigating the effects of an 8-week exercise or 21-day medication intervention on brain function and cognitive performance in individuals with addictive behaviors.
Through completion of these projects, Dr. London and Dr. Mooney aim to identify an exercise or medication intervention as a potential aid for the treatment of stimulant dependence.
Partners
University of California, Los Angeles
Investigators
Edythe D. London, PhD and Larissa J. Mooney, MD
Phase 2, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial of Nepicastat for Cocaine Dependence
CLARE|MATRIX (as Matrix Institute on Addictions) was one of 10 national sites selected to participate in a medication trial designed to evaluate the safety and effectiveness of Nepicastat (SYN-117) in increasing the proportion of cocaine dependent participants who either reduced, or achieved abstinence of, cocaine use after 11 weeks of participation.
CLARE|MATRIX enrolled a total of 26 participants from June 2013 to May 2014; enrolling 8 more participants than originally contracted to enroll, and securing the position of the top recruiting site participating in the trial. Eighty percent of the 26 enrolled participants completed the study.
Partners
National Institute on Drug Abuse/National Institute of Health
VA Cooperative Studies Program
Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study
CLARE|MATRIX (as Matrix Institute on Addictions) participated in a Phase II, 26-28 week, randomized, double-blind, medication trial aimed at evaluating the safety and effectiveness of Vigabatrin, combined with counseling, in increasing the proportion of cocaine dependent participants who achieved abstinence of cocaine use after 7-9 weeks of study participation.
CLARE|MATRIX was one of 13 sites selected by NIDA/NIH to participate, and completed participation with a total enrollment of 19 participants and retention rate of 84 percent.
Partners
Catalyst Pharmaceutical Partners, Inc.
National Institute on Drug Abuse/National Institute of Health
VA Cooperative Studies Program